Compare Symbotic Inc (SYM) vs Tango Therapeutics Inc. (TNGX) Price & Performance

SYM trades at $40.89, down 32% year-to-date and near 52-week lows, with bearish technical signals dominating. Fundamentally, the company shows mixed results with a $22.5 billion backlog and 20%+ revenue growth but negative EBITDA of -$48M and net loss of -$17M in 2025. Recent earnings misses and high customer concentration (85% revenue from Walmart) create uncertainty despite analyst optimism.

The stock presents a high-risk opportunity with significant upside potential if execution improves. Analyst consensus targets $60.33 (47% upside) but near-term risks include continued earnings misses, customer concentration, and weak technical momentum. The 2027 inflection point for new system deployments represents the key growth catalyst.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.